Start-up company continues to build CNS pipeline with this third deal.
Synosia Therapeutics acquired a license from Syngenta to develop a potentially novel treatment for Parkinson’s disease.
Synosia will thus assume responsibility for the ongoing clinical development and commercialization of SYN-118 in CNS.
This compound is a hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor. It s already approved in the U.S. and Europe for the treatment of hereditary tyrosinemia type 1. The drug is marketed by Orphan International under the name Orfadin® (nitisinone), under license from Syngenta.
“This compound is a perfect fit for our strategy of using small, smart clinical trials to rapidly establish proof-of-concept and explore the full potential of clinically enabled drugs,” says Ian Massey, CEO and president of Synosia. “We already know a lot about this molecule and by applying innovative clinical designs, together with the latest imaging tools, we can quickly generate clinical information in new therapeutic areas.”
Contingent upon progress, Syngenta will receive milestone payments and royalties upon commercialization.
Synosia says that this is its third pharmaceutical agreement. The company started operations at the beginning of 2007 to develop new treatments for CNS disorders. Synosia reports that it now has a pipeline of seven compounds, with an option on an eighth, following previous deals with Roche and Novartis.
